Kelli Tidwell
Nurse Practitioner · Knoxville, TNNPI 1104074822
Payments from drug & device makers
Across 302 payments — averaging $18.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$624
- Corcept Therapeutics$446
- Novo Nordisk$440
- Dexcom, Inc.$419
- Xeris Pharmaceuticals, Inc.$411
- Mannkind Corporation$373
- plus $3K from 26 others
What the payments were for
- Food & beverage$5,638100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 41 | $624 |
| Corcept Therapeutics | 15 | $446 |
| Novo Nordisk | 33 | $440 |
| Dexcom, Inc. | 20 | $419 |
| Xeris Pharmaceuticals, Inc. | 21 | $411 |
| Mannkind Corporation | 16 | $373 |
| Bayer | 20 | $325 |
| Lilly USA, LLC | 21 | $300 |
| Insulet Corporation | 16 | $293 |
| Amgen(2 entities) | 17 | $290 |
| Novartis | 19 | $257 |
| Sanofi-aventis U.S. LLC | 13 | $216 |
| Medtronic | 3 | $204 |
| Radius Health, Inc. | 9 | $191 |
| Cequr Corporation | 2 | $133 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Kyowa Kirin, Inc. | 5 | $82 |
| AstraZeneca(2 entities) | 5 | $72 |
| Ascendis Pharma Endocrinology Inc | 4 | $72 |
| Amphastar Pharmaceuticals, Inc. | 4 | $68 |
| Nevro Corp. | 4 | $67 |
| Tandem Diabetes Care, Inc. | 1 | $49 |
| Chiesi USA, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $29 |
| Globus Medical | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Rhythm Pharmaceuticals, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $16 |
| Echosens North America, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$218
- AFREZZA$123
- EVKEEZA$122
- MINIMED 780G$111
How this compares
$5,649 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 167 | $236,476 |
| OzempicSemaglutide | 129 | $202,090 |
| JardianceEmpagliflozin | 62 | $79,219 |
| TrulicityDulaglutide | 43 | $61,049 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $59,686 |
| Humalog Kwikpen U-200Insulin Lispro | 19 | $57,203 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $48,313 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $39,682 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 43 | $35,730 |
| NovologInsulin Aspart | 89 | $32,241 |
| Humulin R U-500Insulin Regular, Human | 19 | $27,073 |
| Novolog FlexpenInsulin Aspart | 79 | $26,757 |
| FarxigaDapagliflozin Propanediol | 23 | $22,672 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 20 | $20,441 |
| Repatha SureclickEvolocumab | 23 | $19,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $300 | $315,782272 claims |
| Novo NordiskOzempic, Novolog | $440 | $234,331218 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $29 | $112,26290 claims |
| AstraZenecaFarxiga | $72 | $22,67223 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $216 | $20,05645 claims |
| Mannkind CorporationAfrezza | $373 | $10,40312 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $2,329194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Knoxville
- Karen RodenKnoxville$265K
- Erica HembreeKnoxville$125K
- Robin LovedayKnoxville$56K
- Tiffany SteelmanKnoxville$21K
- Jennifer BerryKnoxville$19K
- Erica HillKnoxville$13K
- Amy HatcherMurfreesboro$1.1M
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Brooke FaughtNashville$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.